This approach demonstrates a superior therapeutic strategy for an ATR inhibitor to selectively target treatment‐resistant hypoxic cancer cells whilst providing local bystander effect on neighbouring non‐hypoxic TNBC cells, and in addition provide a means of reducing systemic toxicities associated with ATR inhibitors. This evidence concerns the gene ATR and cancer.